GetTopicDetailResponse(id=2e03101113c7, topicName=食管胃癌, introduction=食管胃癌, content=null, image=null, comments=4, allHits=1071, url=https://h5.medsci.cn/topic?id=101113, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=79394, tagList=[TagDto(tagId=79394, tagName=食管胃癌)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2226852, encodeId=751e222685290, content=<a href='/topic/show?id=2e03101113c7' target=_blank style='color:#2F92EE;'>#食管胃癌#</a> <a href='/topic/show?id=a17911933e3f' target=_blank style='color:#2F92EE;'>#CCNE1#</a> <a href='/topic/show?id=5cd01193383b' target=_blank style='color:#2F92EE;'>#EGC#</a>, objectTitle=食管胃癌檢出CCNE1擴(kuò)增有什么意義？關(guān)于預(yù)后和靶向/免疫治療療效, objectType=article, longId=844007, objectId=95ad84400e4a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240920/1726828779373_8538692.png, objectUrl=/article/show_article.do?id=95ad84400e4a, replyNumber=0, likeNumber=71, createdTime=2024-09-21, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=95ad84400e4a, moduleTitle=食管胃癌檢出CCNE1擴(kuò)增有什么意義？關(guān)于預(yù)后和靶向/免疫治療療效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=95ad84400e4a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2082968, encodeId=42382082968ca, content=<a href='/topic/show?id=2e03101113c7' target=_blank style='color:#2F92EE;'>#食管胃癌#</a>, objectTitle=Gastric Cancer：患者報(bào)告的生活質(zhì)量在食管胃癌的生存預(yù)后作用：來(lái)自POCOP研究, objectType=article, longId=214518, objectId=765d214518fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=765d214518fd, replyNumber=0, likeNumber=103, createdTime=2021-09-05, rootId=0, userName=ms1467340776200723, userId=82ba2500166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=765d214518fd, moduleTitle=Gastric Cancer：患者報(bào)告的生活質(zhì)量在食管胃癌的生存預(yù)后作用：來(lái)自POCOP研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=765d214518fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082967, encodeId=c3bf208296e5b, content=<a href='/topic/show?id=2e03101113c7' target=_blank style='color:#2F92EE;'>#食管胃癌#</a>, objectTitle=Lancet Oncol：派姆單抗聯(lián)合療法一線治療HER2陽(yáng)性轉(zhuǎn)移性食管胃癌, objectType=article, longId=194729, objectId=8973194e294c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8973194e294c, replyNumber=0, likeNumber=97, createdTime=2021-02-24, rootId=0, userName=ms1467340776200723, userId=82ba2500166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8973194e294c, moduleTitle=Lancet Oncol：派姆單抗聯(lián)合療法一線治療HER2陽(yáng)性轉(zhuǎn)移性食管胃癌, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=8973194e294c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082966, encodeId=b46d2082966eb, content=<a href='/topic/show?id=2e03101113c7' target=_blank style='color:#2F92EE;'>#食管胃癌#</a>, objectTitle=2019 ESMO 瑞戈非尼120 mg聯(lián)合紫杉醇二線治療晚期食管胃癌，初顯療效, objectType=article, longId=180450, objectId=c1df1804504a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1df1804504a, replyNumber=0, likeNumber=114, createdTime=2020-07-31, rootId=0, userName=ms1467340776200723, userId=82ba2500166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1df1804504a, moduleTitle=2019 ESMO 瑞戈非尼120 mg聯(lián)合紫杉醇二線治療晚期食管胃癌，初顯療效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c1df1804504a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082965, encodeId=eee520829655c, content=<a href='/topic/show?id=2e03101113c7' target=_blank style='color:#2F92EE;'>#食管胃癌#</a>, objectTitle=JCO：Nivolumab和Nivolumab聯(lián)合Ipilimumab治療轉(zhuǎn)移性食管胃癌患者, objectType=article, longId=147192, objectId=187c14e1923f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=187c14e1923f, replyNumber=0, likeNumber=101, createdTime=2019-03-28, rootId=0, userName=ms1467340776200723, userId=82ba2500166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=187c14e1923f, moduleTitle=JCO：Nivolumab和Nivolumab聯(lián)合Ipilimumab治療轉(zhuǎn)移性食管胃癌患者, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=187c14e1923f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
